Efficacy of median nerve hydrodissection by hyalase versus midazolam in the treatment of carpal tunnel syndrome.

Mina Maher Raouf, Amany Khairy Abo-Elhessein, Manal Hasanein, John Ezzat Abskharon, Shady Safwat Hassan, Esraa Ahmed Talaat, Abdel-Raheem Elawamy, Emad Zarief Kamel

Pain management 2023 Feb

filter terms:

Background: The objective was to determine which of midazolam or hyalase could improve the pain score and functional disability in median nerve hydrodissection. Methods: In a double-blind study with two groups, both received bupivacaine 15 mg with either 300 IU hyalase in 2 ml of saline (group HA) or 2 mg of midazolam in 2 ml of sterile saline (group MZ). Results: Statistically significantly lower post-injection Visual Analog Scale scores in group MZ compared with group HA at all follow-ups. Group MZ had significantly lower functional disability scores than group HA. Conclusion: Both drugs yielded favorable results. Midazolam was more impactful in alleviating pain and reducing functional disability up to 6 months.

Citation

Mina Maher Raouf, Amany Khairy Abo-Elhessein, Manal Hasanein, John Ezzat Abskharon, Shady Safwat Hassan, Esraa Ahmed Talaat, Abdel-Raheem Elawamy, Emad Zarief Kamel. Efficacy of median nerve hydrodissection by hyalase versus midazolam in the treatment of carpal tunnel syndrome. Pain management. 2023 Feb;13(2):77-86